Anbio Biotechnology(NNNN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | 23.46 | EPS (ttm) | 0.16 | Insider Own | 9.57% | Shs Outstand | 43.9M | Perf Week | 3.23% |
| Market Cap | 0.55B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 39.7M | Perf Month | -37.66% |
| Enterprise Value | 0.54B | PEG | - | EPS next Q | - | Inst Own | 0.16% | Short Float | 0.08% | Perf Quarter | -64.28% |
| Income | 0.01B | P/S | 56.73 | EPS this Y | - | Inst Trans | 2.54% | Short Ratio | 0.21 | Perf Half Y | -86% |
| Sales | 0.01B | P/B | 4.76 | EPS next 5Y | - | ROA | 26.08% | Short Interest | 0.03M | Perf YTD | -87.23% |
| Book/sh | 0.81 | P/C | 39.52 | EPS past 3/5Y | -12.86% 23.44% | ROE | 27.01% | 52W High | -91.42% ($44.73) | Perf Year | -83.55% |
| Cash/sh | 0.1 | P/FCF | - | Sales past 3/5Y | -26.67% 16.85% | ROIC | 20.29% | 52W Low | 24.27% ($3.09) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | 83.11 | EPS Y/Y TTM | 170.13% | Gross Margin | 87.06% | Volatility(W/M) | 10.81% 12.45% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 55.29 | Sales Y/Y TTM | 10.1% | Oper. Margin | 66.47% | ATR (14) | 0.54 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 344.31 | EPS Q/Q | 321.09% | Profit Margin | 73.75% | RSI (14) | 35.27 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 344.31 | Sales Q/Q | 87.39% | SMA20 | -8.47% ($4.2) | Beta | 5.35 | Target Price | - |
| Payout | - | Debt/Eq | 0 | Earnings | - | SMA50 | -31.76% ($5.63) | Rel Volume | 0.23 | Prev Close | $3.71 |
| Employees | 27 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -78.3% ($17.7) | Avg Volume(3M) | 0.15M | Price | $3.84 |
| IPO | 2025/2/19 | Option/Short | No/Yes | Trades | 303 | Volume | 35,202 | Change | 3.5% |
🧪 A Germany-based diagnostics company that supplies in vitro diagnostic (IVD) products. It develops and supplies rapid diagnostic kits as well as immunoassay and molecular diagnostic solutions, and sells diagnostic products in global markets including Europe, Asia, and the Americas. It is a newly listed company in the in vitro diagnostics field.
Over the past 1 year, on the lower side
91% below its 1-year high.
Traded less than usual. That is 23% of its average volume.
NNNN makes money exceptionally well
Of every $100 in sales, $66.47 is kept as operating profit.
Tap to view numbers
The price is about the industry average
For a company earning $100 a year, you would pay $2,346. Peers typically go for $2,952.
Tap to view numbers
Holding long would have lost money
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Institutions barely hold it
Institutions hold 0.2%.
Tap to view numbers
It ranks #29 of 51 in the industry
Based on market cap of $553M.
NNNN#29 Anbio Biotechnology $553M PER 23.5 
ANGO#30 Angiodynamic Inc $510M PER - 
EMBC#31 Embecta Corp $366M PER 4.3 
SMTI#32 Sanara MedTech Inc $302M PER - 
ZJYL#33 Jin Medical International Ltd $301M PER 12.7 
FAQ
What kind of company is NNNN?
NNNN belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.
What is the market cap of NNNN?
The market cap of NNNN is approximately $553M, ranking 3,076 within its sector.
What is the P/E ratio of NNNN?
NNNN has a P/E ratio of approximately 23.5x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for NNNN?
NNNN has recorded a 52-week high of $44.73 and a low of $3.09.
